Donepezil for irradiated brain tumor survivors: A phase III randomized placebo-controlled clinical trial

Journal of Clinical Oncology

Volumn 33, Issue 15, 2015, Pages 1653-1659

  Rapp, Stephen R ^a   Case, L Doug ^a   Peiffer, Ann ^a   Naughton, Michelle M ^a   Chan, Michael D ^a   Stieber, Volker W ^b   Moore, Dennis F ^c   Falchuk, Steven C ^d   Piephoff, James V ^e   Edenfield, William J ^f   Giguere, Jeffrey K ^f   Loghin, Monica E ^g   Shaw, Edward G ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Novant Health   (United States)

^c WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^d CHRISTIANA CARE HEALTH SYSTEM   (United States)

^e MERCY HOSPITAL   (United States)

^f Cancer Centers of the Carolinas   (United States)

^g UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; PLACEBO; CHOLINESTERASE INHIBITOR; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

ADULT; AGE; ARTICLE; ATTENTION; BRAIN CANCER; BRAIN METASTASIS; BRAIN RADIATION; CANCER SURVIVOR; CAUCASIAN; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MARRIED PERSON; MEMORY; MOTOR ACTIVITY; MOTOR PERFORMANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECALL; TREATMENT OUTCOME; VELOCITY; AGED; BRAIN NEOPLASMS; CLINICAL TRIAL; COGNITION DISORDERS; DRUG EFFECTS; LEARNING; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEUROPSYCHOLOGICAL TEST; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDANS; LEARNING; MALE; MEMORY; MIDDLE AGED; NEOPLASM METASTASIS; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84933497918     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.4508     Document Type: Article

References (33)

1. DeSantis CE, Lin CC, Mariotto AB, et al: Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64:252-271, 2014
2. Perry A, Schmidt RE: Cancer therapy-associated CNS neuropathology: An update and review of the literature. Acta Neuropathol 111:197-212, 2006
3. Ahles TA, Root JC, Ryan EL: Cancer- and cancer treatment-associated cognitive change: An update on the state of the science. J Clin Oncol 30:3675-3686, 2012
4. Johnson BE, Becker B, Goff WB 2nd, et al: Neurologic, neuropsychologic, and computed cranial tomography scan abnormalities in 2- to 10-year survivors of small-cell lung cancer. J Clin Oncol 3:1659-1667, 1985
5. Laukkanen E, Klonoff H, Allan B, et al: The role of prophylactic brain irradiation in limited stage small cell lung cancer: Clinical, neuropsychologic, and CT sequelae. Int J Radiat Oncol Biol Phys 14:1109-1117, 1988
6. Meyers CA, Smith JA, Bezjak A, et al: Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: Results of a randomized phase III trial. J Clin Oncol 22:157-165, 2004
7. Dimberg Y, Lärkfors L: Effects of irradiation on cholinergic neurons and nerve growth factor mRNA in mouse foetal brain aggregation cultures. Int J Radiat Biol 66:793-800, 1994
8. Madsen TM, Kristjansen PE, Bolwig TG, et al: Arrested neuronal proliferation and impaired hippocampal function following fractionated brain irradiation in the adult rat. Neuroscience 119:635-642, 2003
9. Pinkham MB, Bertrand KC, Olson S, et al: Hippocampal-sparing radiotherapy: The new standard of care for World Health Organization grade II and III gliomas? J Clin Neurosci 21:86-90, 2014
10. Brown PD, Pugh S, Laack NN, et al: Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: A randomized, double-blind, placebo-controlled trial. Neuro Oncol 15:1429-1437, 2013
11. Shaw EG, Rosdhal R, D'Agostino RB Jr, et al: Phase II study of donepezil in irradiated brain tumor patients: Effect on cognitive function, mood, and quality of life. J Clin Oncol 24:1415-1420, 2006
12. Scarpini E, Scheltens P, Feldman H: Treatment of Alzheimer's disease: Current status and new perspectives. Lancet Neurol 2:539-547, 2003
13. Birks J, Harvey RJ: Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 1:CD001190, 2006
14. Howard R, McShane R, Lindesay J, et al: Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 366:893-903, 2012
15. Leroi I, Brandt J, Reich SG, et al: Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 19:1-8, 2004
16. Krupp LB, Christodoulou C, Melville P, et al: Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 63:1579-1585, 2004
17. Zhang L, Plotkin RC, Wang G, et al: Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury. Arch Phys Med Rehabil 85:1050-1055, 2004
18. Grön G, Kirstein M, Thielscher A, et al: Cholinergic enhancement of episodic memory in healthy young adults. Psychopharmacology (Berl) 182:170-179, 2005
19. Ceravolo R, Volterrani D, Tognoni G, et al: Cerebral perfusional effects of cholinesterase inhibitors in Alzheimer disease. Clin Neuropharmacol 27:166-170, 2004
20. Brandt J: The Hopkins Verbal Learning Test: Development of a new memory test with six equivalent forms. Clin Neuropsychol 5:125-142, 1991
21. Saxton J, Becker JT, Wisniewski SR: The ROCF and dementia, in Knight JA, Kaplan E (eds): The Handbook of Rey-Osterrieth Complex Figure Usage: Clinical and Research Applications. Lutz, FL, Psychological Assessment Resources, 2003, pp 659-682
22. Reitan R: Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 8:271-276, 1958
23. Ruff RM, Light RH, Parker SB, et al: Benton Controlled Oral Word Association Test: Reliability and updated norms. Arch Clin Neuropsychol 11:329-338, 1996
24. Wechsler D: Wechsler Adult Intelligence Scale-III (WAIS-III). New York, NY, Psychological Corporation/Harcourt, 1996
25. Matthews CG, Klove H: Instruction Manual for the Adult Neuropsychological Test Battery. Madison, WI, University of Wisconsin Medical School, 1964
26. Pocock SJ: Group sequential methods in the design and analysis of clinical trials. Biometrika 64:191-199, 1977
27. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-556, 1979
28. Spotfire S+ SeqTrial User's Manual. Palo Alto, CA, TIBCO Software, 2014
29. Ratitch B, O'Kelly M: Implementation of pattern-mixture models using standard SAS/STAT procedures. http://pharmasug.org/proceedings/2011/SP/PharmaSUG-2011-SP04.pdf
30. SAS/STAT 9.3 SAS User's Guide. Cary, NC, SAS Institute, 2011
31. Correa DD, Shi W, Thaler HT, et al: Longitudinal cognitive follow-up in low grade gliomas. J Neurooncol 86:321-327, 2008
32. Tariot PN, Farlow MR, Grossberg GT, et al: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA 291:317-324, 2004
33. Salloway S, Mintzer J, Cummings JL, et al: Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease. Am J Alzheimers Dis Other Demen 27:421-432, 2012